HomeAI · summaries
Storia in 5 fonti
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome' - Silence Therapeutics (NASDAQ:
Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia…
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
- ·
statnews.com
Silence Therapeutics aims at Takeda with new data in rare blood cancer
A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
